

Industry Sponsored Symposia

Saturday, October 4, 2025

Industry Symposium

17:30 – 18:30

Room A1

Benefits of a combination of xyloglucan and pea protein in functional intestinal disorders (Reckitt)

Chairs: Chloé Melchior



17:30 - 17:35

Introduction

Chloé Melchior

17:35 - 18:15

Latest thinking on DGBIs & new treatments

Chloé Melchior

18:15 - 18:30

Q&A, Key observations and closing remarks

Chloé Melchior

Industry Sponsored Symposia Sunday, October 5, 2025

Industry Symposium

10:00 – 11:00 Room Dublin
Charting the course in IBD: Achieving early and sustained control with IL-23 inhibitors (AbbVie)
 Chairs: Laurent Peyrin-Biroulet
 Sara El Ouali
 Gareth Parkes



10:00 - 10:05
Welcome and introduction

Laurent Peyrin-Biroulet

10:05 - 10:20
Fast-tracking patients to improved outcomes? The benefits of early intervention with IL-23 inhibitors in IBD

Sara El Ouali

10:20 - 10:35
Pole position: Head-to-head studies of IL-23 inhibitors in IBD

Laurent Peyrin-Biroulet

10:35 - 10:50
Going the extra mile: Evidence of the durability and safety of IL-23 inhibitors in IBD

Gareth Parkes

10:50 - 10:58
Audience Q&A
 Laurent Peyrin-Biroulet
 Sara El Ouali
 Gareth Parkes

10:58 - 11:00
Summary and close
 Laurent Peyrin-Biroulet

Industry Symposium

10:00 – 11:00 Room A7
From Adiposity to Hepatic Health: Exploring the Pleiotropic Clinical Impact of Semaglutide (Novo Nordisk)
 Chairs: Naim Alkhouri



10:00 - 10:05
Welcome and Introduction
 Naim Alkhouri

10:05 - 10:25
Semaglutide in Obesity: Clinical efficacy and beyond
 Gema Frühbeck

10:25 - 10:45
Semaglutide in MASH: A paradigm shift in Hepatometabolic Care?

Naim Alkhouri

10:45 - 10:55
Panel Discussion

Naim Alkhouri
 Gema Frühbeck

10:55 - 11:00
Closing Remarks and Wrap up
 Naim Alkhouri

Industry Symposium

10:00 – 11:00 Room A8
Advancing treatment efficacy in ulcerative colitis: Lessons from VARSITY and beyond (Takeda)
 Chairs: Stefan Schreiber



10:00 - 10:10
Welcome and introduction
 Stefan Schreiber

10:10 - 10:25
Characterizing response to therapy: What's the hype?
 Parambir Dulai
 Maria Paraskevopoulou

10:25 - 10:40
Understanding disease dynamics after treatment initiation
 Stefan Schreiber
 Maria Paraskevopoulou

10:40 - 10:55
Panel discussion and audience Q&A
 Stefan Schreiber
 Parambir Dulai
 Maria Paraskevopoulou

10:55 - 11:00
Closing remarks
 Stefan Schreiber

Industry Symposium

12:00 – 13:00 Room Helsinki
Driving the evolution of treatment goals in UC management: Long-term remission with mirikizumab (Eli Lilly and Company)
 Chairs: Fernando Magro



12:00 - 12:10
Strive towards comprehensive control in UC
 Fernando Magro
 Jimmy Limdi
 Sebastian Zeissig

12:10 - 12:30

Explore mirikizumab's efficacy across early and intermediate endpoints with real-world insights

Fernando Magro
Jimmy Limdi
Sebastian Zeissig

12:30 - 12:50

Delve into how mirikizumab meets emerging goals: from trials to practice

Fernando Magro
Jimmy Limdi
Sebastian Zeissig

12:50 - 13:00

Summary and Q&A

Fernando Magro
Jimmy Limdi
Sebastian Zeissig

Industry Symposium

12:00 – 13:00

Room Dublin

JAK inhibitors in IBD: Overtaking inflammation from the start (AbbVie)

Chairs: Silvio Danese
Iris Dotan
Yamile Zabana Abdo



12:00 - 12:05

Welcome and introduction

Silvio Danese

12:05 - 12:33

Hitting the road in IBD: Evidence for using JAK inhibition early in the disease course

Silvio Danese
Iris Dotan

12:33 - 12:53

Going the extra mile: Evidence from JAK inhibitors long-term efficacy and safety data in IBD

Silvio Danese
Yamile Zabana Abdo

12:53 - 12:58

Audience Q&A

Silvio Danese
Iris Dotan
Yamile Zabana Abdo

12:58 - 13:00

Summary and close

Silvio Danese

Industry Symposium

12:00 – 13:00

Room A1

Bridging the Gap in EoE: Innovative Strategies for Seamless Transition of Care (Sanofi Regeneron)

Chairs: Thomas Greuter
Edoardo Vincenzo Savarino
Carla Giordano



12:00 - 12:05

Welcome

Thomas Greuter

12:05 - 12:35

Understanding Type 2 Inflammation in EoE: A Case-Based Discussion

Thomas Greuter
Edoardo Vincenzo Savarino
Carla Giordano

12:35 - 12:50

Current and Emerging Treatment Options in EoE

Thomas Greuter

12:50 - 13:00

Audience Question and Answer

Thomas Greuter
Edoardo Vincenzo Savarino
Carla Giordano

Industry Symposium

12:00 – 13:00

Room A6

Navigating the IL-23 universe: breaking frontiers in ulcerative colitis (Johnson and Johnson)



12:00 - 12:04

Welcome and introduction

Joana Torres

12:04 - 12:10

Clearing the nebula: the role of IL-23 in the pathophysiology of IBD

Alexander Moschen

12:10 - 12:24

Deep-space exploration: expanding the options in ulcerative colitis

Catherine Reenaers
Joana Torres

12:24 - 12:37

Finding the solar core: the importance of stringent endpoints in ulcerative colitis

Alexander Moschen
David T. Rubin

12:37 - 12:57

Transmission from the IBD space station: real-world experiences with IL-23 inhibitors

David T. Rubin
Joana Torres
Alexander Moschen
Catherine Reenaers
12:57 - 13:00

Summary and close
Alexander Moschen

Industry Symposium

12:00 - 13:00 Room A8
Advanced care through gut healing in Crohn's disease (Takeda)



12:00 - 12:05

Welcome and introductions
Edward V Loftus Jr

12:05 - 12:15

Defining success: rethinking disease control in Crohn's disease
Edward V Loftus Jr

12:15 - 12:30

Planning for success: the benefits of acting early
Bram Verstockt

12:30 - 12:45

Shaping success: importance of individualized treatment decision-making
Britt Christensen

12:45 - 12:55

Panel discussion
Edward V Loftus Jr
Bram Verstockt
Britt Christensen

12:55 - 13:00

Summary and close
Edward V Loftus Jr

Meet the Experts

13:00 - 13:30 Exhibition
Meet The Experts & Innovation Hub Presentation

Meet the Experts

15:00 - 15:30 Exhibition
Meet the Experts

Meet the Experts

16:30 - 17:00 Exhibition
Meet the Experts

Industry Symposium

18:30 - 19:30 Room Budapest
TL1A: An emerging pathway in IBD (MSD)
Chairs: Stefan Schreiber
Remo Panaccione



18:30 - 18:35

Welcome and introductions
Stefan Schreiber
Remo Panaccione

18:35 - 18:45

IBD as a systemic condition
Johan Burisch

18:45 - 19:00

TL1A pathway: An important piece of the puzzle
Giorgos Bamias

19:00 - 19:10

Breaking the therapeutic ceiling in IBD
Manuel Barreiro de Acosta

19:10 - 19:20

Questions for the panel
Remo Panaccione

19:20 - 19:25

Q&A from the audience
Stefan Schreiber

Industry Sponsored Symposia Monday, October 6, 2025

Meet the Experts
09:30 – 10:00 Exhibition
Meet the Experts

Meet the Experts
11:00 – 11:30 Exhibition
Meet the Experts & Innovation Hub Presentation

Meet the Experts
12:30 – 13:00 Exhibition
Innovation Hub Presentation

Industry Symposium
13:00 – 14:00 Room Dublin
Paving the way to comprehensive management in CD: Long-term remission with mirikizumab (Eli Lilly and Company)
Chairs: Geert R. D'Haens

13:00 - 13:20
Demonstrate understanding of comprehensive management of CD
Geert R. D'Haens
Marc Ferrante
Raja Atreya

13:20 - 13:35
Review how mirikizumab provides symptomatic relief: from trials to clinical practice
Geert R. D'Haens
Marc Ferrante
Raja Atreya

13:35 - 13:50
Examine mirikizumab's efficacy in achieving current and future endpoints
Geert R. D'Haens
Marc Ferrante
Raja Atreya

13:50 - 14:00
Summary and Q&A
Geert R. D'Haens
Marc Ferrante
Raja Atreya

Industry Symposium
13:00 – 14:00 Room A1
Rethinking IBD Treatment: Novel Mechanisms and the Future of IBD Therapy (Sanofi)
Chairs: Marla C. Dubinsky

13:00 - 13:05
Welcome and Opening Remarks
Marla C. Dubinsky

13:05 - 13:20
Current Treatment Landscape and Unmet Needs in IBD
Millie Long

13:20 - 13:30
Panel Discussion
Marla C. Dubinsky
Millie Long
Joana Torres

13:30 - 13:50
Diversifying the IBD Therapeutic Landscape: Emerging Molecular Targets
Joana Torres

13:50 - 14:00
Panel Discussion, Q&A, and Closing
Marla C. Dubinsky
Millie Long
Joana Torres

Industry Symposium
13:00 – 14:00 Room A3
An oral option for UC relief: evaluating treatment with an S1P receptor modulator (Pfizer Inc.)
Chairs: Dominik Bettenworth

13:00 - 13:00
Unmet needs in UC: why the journey matters
Dominik Bettenworth

13:00 - 13:10
Data that changed the UC conversation: the ELEVATE clinical trials
Remo Panaccione

13:10 - 13:20
Expanding the evidence in UC: the ES101002 clinical trial
Alissa Walsh

13:20 - 13:50

Personalising the treatment pathway for patients with moderately-to-severely active UC

Case 1: Relapsing proctitis: when steroids fail

Case 2: Adolescence and active disease

Case 3: Oral preference: oral treatment options in complex UC

Dominik Bettenworth

Remo Panaccione

Alissa Walsh

13:50 - 14:00

S1P receptor modulators in practice: what's next for patient-centred UC care?

Dominik Bettenworth

Remo Panaccione

Alissa Walsh

Industry Symposium

13:00 – 14:00

Room A6

Navigating the IL-23 universe: breaking frontiers in Crohn's disease (Johnson and Johnson)



13:00 - 13:03

Welcome and introduction

Laurent Peyrin-Biroulet

13:03 - 13:08

Navigating the IBD universe: from before the advent of IL-23 to the present and beyond

Alessandro Armuzzi

13:08 - 13:13

The fabric of the cosmos: IL-23 as the master cytokine in IBD

Sebastian Zeissig

13:13 - 13:25

Expanding the patient frontier: long-term clinical outcomes for Crohn's disease

Laurent Peyrin-Biroulet

Yamile Zabana

13:25 - 13:37

Expanding the physician frontier: raising the bar for outcomes in Crohn's disease

Alessandro Armuzzi

Sebastian Zeissig

13:37 - 13:57

Finding the supernova in Crohn's disease: real-life experience in the IL-23 era

Alessandro Armuzzi

Laurent Peyrin-Biroulet

David T. Rubin

Yamile Zabana

Sebastian Zeissig

13:57 - 14:00

Summary and close

Alessandro Armuzzi

Industry Symposium

13:00 – 14:00

Room A7

A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration (Catalyst Medical Education, LLC)



13:00 - 13:10

Introduction. The Growing Burden of MASLD/MASH: A Call to Action

Naim Alkhouri

13:10 - 13:25

Improving Diagnosis in the Era of Disease-specific Therapy

Jörn Schattenberg

13:25 - 13:40

The New Treatment Paradigm with THR-β Agonists and Other Disease-specific Therapies

Frank Tacke

13:40 - 13:50

Integrating MASLD/MASH-Specific Therapy into Guideline-Aligned Real-World Practice

Naim Alkhouri

13:50 - 14:00

Conclusions and Q&A

Naim Alkhouri

Frank Tacke

Jörn Schattenberg

Meet the Experts

14:00 – 14:30

Exhibition

Meet The Experts & Innovation Hub Presentation

Meet the Experts

15:30 – 16:00

Exhibition

Meet the Experts

Meet the Experts

17:00 – 17:30

Exhibition

Meet the Experts

Industry Symposium

17:30 – 18:30

Room Helsinki

From Evolution to Revolution: New Mechanisms of Action in Ulcerative Colitis (Abivax)



17:30 - 17:35

Welcome & Introduction

Bruce E. Sands

17:35 - 17:45

The Evolution of UC Drug Development

Raja Atreya

17:45 - 18:00

A New Chapter: Phase 3 Induction Results with Obefazimod

Bruce E. Sands

18:00 - 18:20

Exploring Subgroup Outcomes and Potential for Combination Therapy

Silvio Danese

18:20 - 18:30

Q&A

Raja Atreya

Bruce E. Sands

Silvio Danese

Industry Symposium

17:30 – 18:30

Room A1

When & for Whom: Intravenous vs Subcutaneous Therapies in IBD Maintenance (Celltrion)

Chairs: Stefan Schreiber



17:30 - 17:35

Introduction

Stefan Schreiber

17:35 - 17:50

The right time and the right patient: what can be considered?

Stefan Schreiber

17:50 - 18:10

Two sides of the same coin: A comparative look at IV vs SC from real-world experience

Julien Kirchgesner

18:10 - 18:20

Difference in societal impact between IV vs SC treatments

Christian P. Selinger

18:20 - 18:30

Panel discussion / Q&A

Stefan Schreiber

Julien Kirchgesner

Christian P. Selinger

Industry Symposium

17:30 – 18:30

Room A2

Innovations in IBD Therapy: The Story of TL1A - from Discovery to Potential Future Care (F. Hoffmann-La Roche Ltd)

Chairs: Jean-Frédéric Colombel
Remo Panaccione
Beatriz Gros



17:30 - 17:45

The Past – Discovery of TL1A, early evidence for its role in inflammation and fibrosis

Jean-Frédéric Colombel

Remo Panaccione

Beatriz Gros

17:45 - 18:05

The Present – TL1A in development: Targeting the key features in IBD pathogenesis

Jean-Frédéric Colombel

Remo Panaccione

Beatriz Gros

18:05 - 18:20

The Future - Unlocking new possibilities with TL1A inhibition

Jean-Frédéric Colombel

Remo Panaccione

Beatriz Gros

18:20 - 18:30

Q&A

Jean-Frédéric Colombel

Remo Panaccione

Beatriz Gros

Industry Symposium

17:30 – 18:30

Room A5

Redefining EoE Treatment Success through Real-World Cases (Sanofi Regeneron)

Chairs: Alain Schoepfer



17:30 - 17:35

Welcome & Introduction

Alain Schoepfer

17:35 - 18:20

Identifying and managing active EoE through real-world cases

Alain Schoepfer

Ulrike von Arnim

Salvatore Oliva

18:20 - 18:30

Closing remarks and Q&A

Alain Schoepfer

Industry Symposium

17:30 – 18:30

Room A7

Advances in PBC Management: A Simple Approach (Gilead)Chairs: Holger Hinrichsen
Maria-Carlota Londoño

17:30 - 17:30

Welcome and Introductions

Holger Hinrichsen

17:30 - 17:30

A Gastroenterologist's Guide to PBC

Holger Hinrichsen

17:30 - 17:30

Redefining Possibilities in PBC Management

Holger Hinrichsen

17:30 - 17:30

Making PBC Care Simpler with Seladelpar

Maria-Carlota Londoño

17:30 - 17:30

Q&A

Holger Hinrichsen

Maria-Carlota Londoño

17:30 - 17:30

Conclusions

Holger Hinrichsen

Industry Sponsored Symposia

Tuesday, October 7, 2025

Meet the Experts
 09:30 – 10:00 Exhibition
Meet the Experts & Innovation Hub Presentation

Industry Symposium
 13:00 – 14:00 Room A1
Optimal Approaches to Initial Management of Ulcerative Colitis and *Clostridioides difficile* Infection (Tillotts Pharma AG)



13:00 - 13:30
Optimal Approaches to Initial Management of Ulcerative Colitis
 Jonas Halfvarson

13:30 - 14:00
Optimal management of *C. difficile* infection; Are your IBD patients at risk?
 Mark Wilcox